Medical Oncology

ITP   

Questions discussed in this category


Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.

For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?

Would you consider high-dose dexamethasone (deliberating adverse effects of antenatal steroids) or move to next-line therapies?